New Method to Measure Lung Antibodies from the Lower Airways Could Boost Development of Mucosal Vaccines
November 16, 2026 | 3 min read
A noninvasive method of measuring antigen-specific antibodies in the lower airways has shown promise in a proof-of-concept study published in eBioMedicine.
The finding may help boost the development of mucosal vaccines that can be administered through the nose or via inhalation, an important step forward in ensuring vaccines tackle infection at the site of entry.
“While currently employed parenteral vaccines against respiratory viruses protect against severe disease, they provide limited protection against infection and onward transmission as they fail to elicit robust antibody responses at the site of viral entry,” explained the Swedish authors of the study.
Mucosal vaccines induce both systemic and local immunity but, as the authors continued, “evaluations of such vaccines are constrained by the lack of practical methods for assessing mucosal immune responses, particularly in the lower airways.”
While induced sputum is an option, it is not ideal because it mainly reflects secretions from larger and more proximal airways and can be prone to contamination from the upper airways.
In this study, the investigators used a noninvasive method called Particles in Exhaled Air (PExA) to capture aerosolized respiratory tract lining fluid from the distal airways. Basically, the strategy calls for the user to wear a nose clip and breathe into the PExA instrument via a mouthpiece and two-way non-rebreathing valve. Participants inhale HEPA-filtered air to remove particles from ambient air before performing the test. The samples are then assessed to quantify antigen-specific IgA and IgG.
Samples from 28 health care workers, 18 of whom had confirmed COVID-19, influenza, or RSV, were used for the analysis.
The authors found:
- Antigen-specific IgA and IgG measurements in PExA samples showed low variability.
- Strong correlations were observed between PExA and serum IgG, which the authors believe may be consistent with a systemic contribution to lower-airway IgG levels.
- In contrast, IgA correlations were more modest, which the authors think could reflect local IgA production in the lungs.
- IgG and IgA correlated between PExA and nasal secretions, while the IgA/IgG ratio was higher in nasal secretions, consistent with expected isotype distribution in upper and lower airways.
“By overcoming key barriers to lower-airway sampling, this approach establishes a practical means of studying mucosal immunity and evaluating vaccines designed to induce mucosal immune responses in both upper and lower airways,” concluded the researchers.
They call for additional study to establish the broader applicability of the test and its potential utility in clinical or interventional research settings, including the evaluation of next-generation mucosal vaccines.
The next step of your respiratory therapist journey begins now.
The AARC can help you discover your unique path and connect you with thousands of other dedicated RTs.